AorTx, Inc. was formed to develop an aortic valve that could be delivered both transapically and percutaneously. AorTx, Inc. was acquired by Hansen Medical, Inc. (NASDAQ: HNSN).
Atritech, Inc. developed the WATCHMAN, a proprietary minimally invasive device designed to prevent thrombi (blood clots) that form in the left atrial appendage of the heart during an atrial fibrillation event. Atritech, Inc. was acquired by Boston Scientific Corporation (NYSE: BSX).
CathWorks Ltd. is developing an image-based fractional flow reserve (FFR) measurement designed to replace the pressure wire-based, drug-induced measurement currently performed. The CathWorks angiogram-based FFR (FFRangio) technology provides a less-invasive assessment tool to improve real-time functional assessment that guides treatment decisions and to make coronary catheterization procedures safer, shorter, more accurate, and more comprehensive.
CD Diagnostics, Inc. became a fully integrated diagnostics company focused on developing immunoassays that improve patient outcomes. The company developed a novel biomarker detection technology for rapid diagnosis of periprosthetic joint infection and was acquired by Zimmer Biomet (NYSE: ZBH) in 2016.
Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The FDA-cleared CorPath System brings robotic precision to vascular procedures as the company aims to revolutionize treatment of emergent conditions by providing specialized and timely medical care to patients around the world. Corindus completed an IPO in 2015 (NYSE: CVRS) and was acquired in 2019 by Siemens Healthineers for approximately $1.1 billion.
CV Ingenuity Corp., located in Palo Alto, CA, was a leading drug-eluting balloon technology company and was acquired by Covidien (NYSE: COV).
Ellipse Technologies, Inc., located in Irvine, CA, developed a non-invasively adjustable magnetic implant platform used to treat a broad spectrum of spinal, orthopedic, and deformity conditions, including limb length discrepancies and scoliosis. The company was acquired by NuVasive, Inc. (NASDAQ: NUVA) in 2016.
Embrella Cardiovascular, Inc. was established to create a new standard-of-care for embolic cerebral protection during cardiovascular procedures. Embrella Cardiovascular, Inc. was acquired by Edwards Lifesciences Corp. (NYSE: EW).
Hotspur Technologies, Inc., located in Mountain View, CA, develops, manufactures, and sells a number of innovative balloon catheter systems for the dialysis access and peripheral arterial disease markets. Hotspur Technologies was acquired by Teleflex Incorporated (NYSE: TFX).
Nellix Endovascular, Inc. has developed a revolutionary device for the less invasive treatment of Abdominal Aortic Aneurysms (AAA) and Thoracic Aortic Aneurysms (TAA). Nellix Endovascular, Inc. was acquired by Endologix, Inc. (NASDAQ: ELGX).
OrthoSpace Ltd., located in Caesarea, Israel, developed an implantable, biodegradable balloon that is deployed in a minimally invasive, outpatient procedure and returns range of motion while relieving pain in patients with massive tears of the rotator cuff. OrthoSpace was acquired by Stryker Corp. (NYSE: SYK) in 2019.
ReVascular Therapeutics, Inc. has pioneered advances in the intravascular treatment of complex lesions and Chronic Total Occlusions (CTOs). The company was purchased by Boston Scientific Corporation (NYSE: BSX).
Reverse Medical Corporation, located in Irvine, CA, has developed a suite of state-of-the-art endovascular treatments for a broad spectrum of neurovascular disorders and carotid artery disease. In January 2012, the company sold a line of neurovascular guide catheters to Covidien (NYSE: COV). Reverse Medical Corporation was acquired in its entirety by Covidien in August 2014.
Setagon, Inc. was developing a next-generation drug delivery system for the emerging market of drug-coated stents. Setagon, Inc. was acquired by Medtronic (NYSE: MDT).
TransMedics Group, Inc. (NASDAQ: TMDX) is the world’s leader in portable ex-vivo warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts, the company was founded to address the unmet need for more and better organs for transplantation, and has developed technologies to improve organ quality, validate organ viability, and increase the utilization of transplant organs for the treatment of end-stage heart, lung, and liver failure.